Document:

<PAGE>
                                                                   EXHIBIT 10.65

           FIRST AMENDMENT TO PRIVATE EQUITY LINE FINANCING AGREEMENT

         This First Amendment to Private Equity Line Financing Agreement (this
"Amendment"), is entered into as of February 28, 2002, between Corixa
Corporation, a Delaware corporation ("Corixa"), and BNY Capital Markets, Inc., a
registered broker dealer organized under the laws of New York and a subsidiary
of The Bank of New York (the "Investor").

         WHEREAS, the Company and the Investor entered into that certain Private
Equity Line Financing Agreement dated as of December 3, 2001 (the "Financing
Agreement"); and

         WHEREAS, the Company and the Investor now desire to amend the Financing
Agreement as provided herein;

         NOW, THEREFORE, in consideration for the foregoing premises, the
representations, warranties, covenants and agreements contained herein and in
the Financing Agreement and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledge, intending to be legally
bound hereby, the parties hereto agree as follows:

         1. Capitalized Terms. Except as otherwise defined in this Amendment,
all capitalized terms used herein shall have the meaning set forth in the
Financing Agreement. All references to the term "Agreement" in the Financing
Agreement shall be deemed to include this Amendment.

         2. Amendment to Section 6.02(a)(II) of the Financing Agreement. Section
6.02(a)(II) of the Financing Agreement, is hereby amended and restated to read
in its entirety as follows:

                  (II) The Company shall not have failed to obtain effectiveness
                  of the Registration Statement within 135 days from the Closing
                  Date, and the Registration Statement, after its initial
                  effectiveness, shall not have lapsed in effect such that sales
                  of all of the Registrable Securities otherwise cannot be made
                  thereunder (whether by reason of the Company's failure to
                  amend or supplement the prospectus included therein in
                  accordance with the Registration Rights Agreement or
                  otherwise) for more than thirty (30) consecutive Trading Days
                  or more than ninety (90) Trading Days in any twelve (12) month
                  period after the Registration Statement becomes effective;

         3. Amendment to Section 7.02(d) of the Financing Agreement. Section
7.02(d) of the Financing Agreement, is hereby amended and restated to read in
its entirety as follows:

                  (d) The Registration Statement shall not have been declared
                  effective by the Commission on or before the date which is 135
                  days from the date of this Agreement; or

         4. Full Force and Effect. Except as expressly modified herein, the
Financing Agreement shall continue in full force and effect in accordance with
its terms. To the extent, there

                                       1
<PAGE>
are any inconsistencies or ambiguities between this Amendment and the Financing
Agreement; the terms of this Amendment shall supersede the Financing Agreement.

         5. Counterparts. This Amendment may be executed in counterparts, each
of which shall be deemed an original instrument, and all of which together shall
constitute one and the same instrument.

         6. Governing Law. This Amendment shall be governed by and construed in
accordance with the internal law of the state of New York, without giving effect
to the principles of conflicts of law thereof.

                            [Signature Page Follows]
<PAGE>
         IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be
executed by the undersigned, thereunto duly authorized, as of the date first
above written.

CORIXA CORPORATION

                                         /s/ Michelle Burris
                                    By:___________________________
                                         Name: Michelle Burris
                                         Title: Senior Vice President and
                                                CEO

BNY CAPITAL MARKETS, INC.

                                    By: /s/ Wesley Pritchett
                                       ___________________________
                                        Name: Wesley Pritchett
                                        Title: Managing Director<PAGE>
                                                                   EXHIBIT 10.66

                FIRST AMENDMENT TO REGISTRATION RIGHTS AGREEMENT

         This First Amendment to Registration Rights Agreement (this
"Amendment"), is entered into as of February 28, 2002, between Corixa
Corporation, a Delaware corporation (the "Company"), and BNY Capital Markets,
Inc., a registered broker dealer organized under the laws of New York and a
subsidiary of The Bank of New York (the "Investor").

         WHEREAS, the Company and the Investor have entered into that certain
Registration Rights Agreement dated as of December 3, 2001 (the "Registration
Rights Agreement"); and

         WHEREAS, the Company and the Investor now desire to amend the
Registration Rights Agreement as provided herein;

         NOW, THEREFORE, in consideration for the foregoing premises, the
representations, warranties, covenants and agreements contained herein and in
the Registration Rights Agreement and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledge, intending to be
legally bound hereby, the parties hereto agree as follows:

         1. Capitalized Terms. Except as otherwise defined in this Amendment,
all capitalized terms used herein shall have the meaning set forth in the
Registration Rights Agreement. All references to the term "Agreement" in the
Registration Rights Agreement shall be deemed to include this Amendment.

         2. Amendment to Definition of "Registrable Securities" in Section 1.1
of the Registration Rights Agreement. The definition of "Registrable Securities"
in Section 1.1 of the Registration Rights Agreement, is hereby amended and
restated to read in its entirety as follows:

                  "Registrable Securities" means all of the shares of Common
                  Stock issued or issuable under the Financing Agreement and any
                  other shares of Capital Stock issued or issuable as a dividend
                  on or with respect to such shares of Common Stock until a
                  registration statement under the Securities Act covering the
                  offer and sale of such shares of Common Stock or Capital Stock
                  has been declared effective by the Commission and all such
                  shares of Common Stock or Capital Stock have been disposed of
                  pursuant to such effective registration statement.

         3. Amendment to Section 4.2 of the Registration Rights Agreement.
Section 4.2 of the Registration Rights Agreement is hereby deleted in its
entirety.

         4. Full Force and Effect. Except as expressly modified herein, the
Registration Rights Agreement shall continue in full force and effect in
accordance with its terms. To the extent, there are any inconsistencies or
ambiguities between this Amendment and the Registration Rights Agreement; the
terms of this Amendment shall supersede the Registration Rights Agreement.

                                       1
<PAGE>
         5. Counterparts. This Amendment may be executed in counterparts, each
of which shall be deemed an original instrument, and all of which together shall
constitute one and the same instrument.

         6. Governing Law. This Amendment shall be governed by and construed in
accordance with the internal law of the state of New York, without giving effect
to the principles of conflicts of law thereof.

                            [Signature Page Follows]

                                       2
<PAGE>
         IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be
executed by the undersigned, thereunto duly authorized, as of the date first
above written.

CORIXA CORPORATION

                                    By: /s/ Michelle Burris
                                       ___________________________
                                         Name: Michelle Burris
                                         Title: Senior Vice President
                                                and CFO

BNY CAPITAL MARKETS, INC.

                                    By: /s/ Wesley Pritchett
                                       ___________________________
                                        Name: Wesley Pritchett
                                        Title: Managing Partner<PAGE>
                                                                  Exhibit 10.67

*CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

VIA FACSIMILE AND FEDERAL EXPRESS

August 6, 2001

Mr. Kazuhiro Endo, Product Planning
Zenyaku Kogyo Co., Ltd.
6-16, Otsuka 5-chome
Bunkyo-ku, Tokyo 112-8650
JAPAN

         LETTER AGREEMENT REGARDING DEVELOPMENT AND LICENSE AGREEMENT
         (THE "AGREEMENT"), ENTERED INTO ON AUGUST 16, 1999, BETWEEN ZENYAKU
         KOGYO., LTD. ("ZENYAKU") AND CORIXA CORPORATION ("CORIXA")

Dear Endo-san:

         It was a pleasure to meet with you at our South San Francisco offices
on May 11, 2001. I thought that we had a productive meeting concerning Corixa's
PVAC development program.

         As we discussed during our meeting, based on [*], Corixa [*]. To
further examine the clinical efficacy of PVAC treatment, Corixa is currently
designing an additional US Phase II clinical trial in a selected population of
psoriasis patients.

         We believe that following your review of the data and reports that we
have provided you from the recent Phase II study, you will [*].

--------
*  Confidential Treatment Requested.
<PAGE>
         Because of [*] Zenyaku may defer the payments that were due under
Section 5.1 of the Agreement on November 16, 2000 and February 16, 2001. Those
payments would be due instead as follows:

         (a)      $[*] will be payable within thirty (30) days following
                  Corixa's written notice to Zenyaku of the [*].

         (b)      $[*]will be payable within thirty (30) days following Corixa's
                  delivery to Zenyaku of the [*]. This payment shall be
                  guaranteed and payable even in the event Zenyaku exercises the
                  termination right set forth below.

         Corixa acknowledges that Zenyaku paid to Corixa $[*] under Section 5.1
of the Agreement and the $[*] milestone payable under Section 5.3 of the
Agreement (less $[*] of withholding tax required by the Japanese tax
authorities), which became due as per the two Letter Agreements dated February
16, 2000 and March 30, 2000, between the Parties. Subject to all terms and
conditions of the Agreement, all payments due under Section 5.1 on and after
August 16, 2001 shall be due as set forth therein.

         Further in connection with Corixa's decision to proceed with an
additional U.S. Phase II clinical trial, we agree that Zenyaku shall have an
additional right to terminate the Agreement under Section 18.4 of the Agreement
at any time during the [*] period following Corixa's delivery to Zenyaku of the
final report of the next US Phase II clinical trial, which right to terminate
shall be (i) exercisable by Zenyaku providing Corixa written notice thereof and
(ii) effective [*] following Corixa's receipt of such notice. Any such
termination shall have the same effect as any other termination contemplated by
Sections 5.1 and 18.4(ii); provided, however, that the delayed payments made to
Corixa that were otherwise due on November 16, 2000 and February 16, 2001 shall
not be considered in calculating the amount that Zenyaku has paid to Corixa
under Section 5.1 from August 16, 2001 up until the date of such termination.

         Except as modified hereby, all other terms and conditions of the
Agreement shall remain in full force and effect.

         This Letter Agreement shall be governed by the laws of the state of
Washington, without regard to conflicts of law principles.

--------
*  Confidential Treatment Requested.
<PAGE>
         We hope that you will find the foregoing proposal acceptable. If so,
please confirm your acceptance by signing this Letter Agreement and returning it
to the undersigned.

                                          Sincerely,

                                          CORIXA CORPORATION

                                          By: /s/ Steven Gillis
                                             ----------------------------------
                                          Steven Gillis
                                          Chairman & CEO

ACKNOWLEDGED AND AGREED:

ZENYAKU KOGYO, CO., LTD.

By: /s/ Kazuhiro Hashimoto
   --------------------------------
Its   Kazuhiro Hashimoto
      President & CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00034-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00034-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00034-of-00352.parquet"}]]